81
Participants
Start Date
October 13, 2008
Primary Completion Date
July 9, 2009
Study Completion Date
July 24, 2009
CP-690,550
Topical treatment once daily for 28 days
CP-690,550
Topical treatment once daily for 28 days
CP-690,550
Topical treatment once daily for 28 days
CP-690,550
Topical treatment twice daily for 28 days
CP-690,550
Topical treatment twice daily for 28 days
CP-690,550
Topical treatment twice daily for 28 days
Placebo Vehicle
Topical treatment once daily for 28 days
Placebo Vehicle
Topical treatment twice daily for 28 days
Wake Forest University Health Sciences, Winston-Salem
Dermatology Consulting Services, High Point
The Imaging Center, High Point
RUSH University Medical Center, Chicago
Central Dermatology, PC, St Louis
DermResearch, Inc., Austin
University of Utah School of Medicine, Salt Lake City
Therapeutics Clinical Research, San Diego
University of California Irvine, Irvine
Oregon Medical Research Center, PC, Portland
Oregon Health & Science University, Portland
Tufts Medical Center, Boston
University of Michigan, Ann Arbor
Minnesota Clinical Study Center, Fridley
Guildford Dermatology Specialists, Surrey
NewLab Clinical Research Inc., St. John's
K.Papp Clinical Research Inc., Waterloo
Innovaderm Research, Inc., Montreal
Siena Medical Research, Montreal
Centre de Recherche Dermatologique du Quebec metropolitain, Québec
Lead Sponsor
Pfizer
INDUSTRY